Published in Lancet on September 06, 2003
Prognostic Models for People With Stable Coronary Artery Disease | NCT01609465
Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med (2004) 9.67
Antihypertensive treatment and secondary prevention of cardiovascular disease events among persons without hypertension: a meta-analysis. JAMA (2011) 4.09
Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients. Eur Heart J (2012) 3.19
Nitric oxide and oxidative stress in vascular disease. Pflugers Arch (2010) 2.29
Heart failure: epidemiology and prevention in India. Natl Med J India (2011) 2.09
Thiazide-type diuretics and beta-adrenergic blockers as first-line drug treatments for hypertension. Circulation (2008) 2.06
Long-term trends in use of and expenditures for cardiovascular medications in Canada. CMAJ (2009) 2.02
Primary and secondary prevention of cardiovascular diseases: a practical evidence-based approach. Mayo Clin Proc (2009) 1.88
Blood pressure and stroke risk among diabetic patients. J Clin Endocrinol Metab (2013) 1.79
Combined angiotensin-converting enzyme inhibition and receptor blockade associate with increased risk of cardiovascular death in hemodialysis patients. Kidney Int (2011) 1.74
The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part II - Therapy. Can J Cardiol (2006) 1.67
Limitations of analyses based on achieved blood pressure: lessons from the African American study of kidney disease and hypertension trial. Hypertension (2011) 1.65
Incremental prognostic value of the exercise electrocardiogram in the initial assessment of patients with suspected angina: cohort study. BMJ (2008) 1.64
Predicting prognosis in stable angina--results from the Euro heart survey of stable angina: prospective observational study. BMJ (2006) 1.61
Peripheral artery disease: current insight into the disease and its diagnosis and management. Mayo Clin Proc (2010) 1.58
The prevention of cardiovascular disease in cancer survivors. Tex Heart Inst J (2012) 1.57
Midcourse correction to a clinical trial when the event rate is underestimated: the Look AHEAD (Action for Health in Diabetes) Study. Clin Trials (2012) 1.54
Race and ethnicity in trials of antihypertensive therapy to prevent cardiovascular outcomes: a systematic review. Ann Fam Med (2007) 1.54
Effect of different angiotensin-converting-enzyme inhibitors on mortality among elderly patients with congestive heart failure. CMAJ (2008) 1.51
Effective management of hypertension with dihydropyridine calcium channel blocker-based combination therapy in patients at high cardiovascular risk. Int J Clin Pract (2008) 1.49
The implications of a growing evidence base for drug use in elderly patients Part 2. ACE inhibitors and angiotensin receptor blockers in heart failure and high cardiovascular risk patients. Br J Clin Pharmacol (2006) 1.43
The impact of Medicare Part D on hospitalization rates. Health Serv Res (2011) 1.43
Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current status. Br J Pharmacol (2010) 1.39
Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring. Br J Cancer (2009) 1.38
RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection. Clin Res Cardiol (2008) 1.34
Should all patients with coronary disease receive angiotensin-converting-enzyme inhibitors? Lancet (2003) 1.27
Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study. Heart (2006) 1.26
Mitogen-activated protein kinase inhibitors improve heart function and prevent fibrosis in cardiomyopathy caused by mutation in lamin A/C gene. Circulation (2010) 1.21
Prevalence, incidence, primary care burden and medical treatment of angina in Scotland: age, sex and socioeconomic disparities: a population-based study. Heart (2006) 1.19
Renin: friend or foe? Heart (2007) 1.16
Cardiovascular drug therapy in the elderly: benefits and challenges. Nat Rev Cardiol (2010) 1.13
Reduction in atherosclerotic events: a retrospective study in an outpatient cardiology practice. Arch Med Sci (2012) 1.12
Costs of inpatient care among Medicare beneficiaries with heart failure, 2001 to 2004. Circ Cardiovasc Qual Outcomes (2009) 1.09
The renin-angiotensin system modulates inflammatory processes in atherosclerosis: evidence from basic research and clinical studies. Mediators Inflamm (2009) 1.05
Adverse prognosis associated with the metabolic syndrome in established coronary artery disease: data from the EUROPA trial. Heart (2007) 1.05
Predictors of heart failure in patients with stable coronary artery disease: a PEACE study. Circ Heart Fail (2009) 1.04
2009 Canadian Hypertension Education Program recommendations: the scientific summary--an annual update. Can J Cardiol (2009) 1.03
Treatment gaps in the management of cardiovascular risk factors in patients with type 2 diabetes in Canada. Can J Cardiol (2010) 1.03
Evaluation of multiple biomarkers of cardiovascular stress for risk prediction and guiding medical therapy in patients with stable coronary disease. Circulation (2011) 1.01
Inclusion of stroke as an outcome and risk equivalent in risk scores for primary and secondary prevention of vascular disease. Circulation (2010) 1.01
Chronic coronary artery disease: diagnosis and management. Mayo Clin Proc (2009) 1.00
Missed opportunities for the secondary prevention of cardiovascular disease in Canada. Can J Cardiol (2007) 0.99
Cardioprotective medication use in hemodialysis patients. Can J Cardiol (2006) 0.98
Different angiotensin-converting enzyme inhibitors have similar clinical efficacy after myocardial infarction. Br J Clin Pharmacol (2007) 0.98
Recent developments in secondary prevention and cardiac rehabilitation after acute myocardial infarction. BMJ (2004) 0.98
Heart failure in South Asia. Curr Cardiol Rev (2013) 0.97
The additional value of routine electrocardiograms in cardiovascular risk management of older people. Scand J Prim Health Care (2008) 0.94
Post-load hyperglycemia as an important predictor of long-term adverse cardiac events after acute myocardial infarction: a scientific study. Cardiovasc Diabetol (2010) 0.94
Impact of aging on the clinical outcomes of Japanese patients with coronary artery disease after percutaneous coronary intervention. Heart Vessels (2013) 0.93
Potential population impact of the UK government strategy for reducing the burden of coronary heart disease in England: comparing primary and secondary prevention strategies. Qual Saf Health Care (2006) 0.91
2013 Korean Society of Hypertension guidelines for the management of hypertension. Part II-treatments of hypertension. Clin Hypertens (2015) 0.90
The past, present and future of renin-angiotensin aldosterone system inhibition. Int J Cardiol (2012) 0.90
High intraluminal pressure via H2O2 upregulates arteriolar constrictions to angiotensin II by increasing the functional availability of AT1 receptors. Am J Physiol Heart Circ Physiol (2008) 0.89
Diabetes nurse case management and motivational interviewing for change (DYNAMIC): results of a 2-year randomized controlled pragmatic trial. J Diabetes (2013) 0.88
Effects of valsartan and perindopril combination therapy on left ventricular hypertrophy and aortic arterial stiffness in patients with essential hypertension. Eur J Clin Pharmacol (2005) 0.88
Antihypertensive medications: benefits of blood pressure lowering and hazards of metabolic effects. Expert Rev Cardiovasc Ther (2009) 0.88
Metabolic syndrome: a marker of patients at high cardiovascular risk. Can J Cardiol (2006) 0.88
Hypertension: empirical evidence and implications in 2014. Open Heart (2014) 0.87
Critical appraisal of C-reactive protein throughout the spectrum of cardiovascular disease. Vasc Health Risk Manag (2006) 0.86
Pattern of Angiotensin-converting enzyme inhibitors induced adverse drug reactions in South Indian teaching hospital. N Am J Med Sci (2012) 0.86
Management standards for stable coronary artery disease in India. Indian Heart J (2016) 0.86
Aliskiren (tekturna), a novel antihypertensive approach to inhibition of the Renin-Angiotensin-aldosterone system. P T (2008) 0.85
Ethnicity and variation in prognosis for patients newly hospitalised for heart failure: a matched historical cohort study. Heart (2005) 0.85
Prevention of cardiovascular disease guided by total risk estimations--challenges and opportunities for practical implementation: highlights of a CardioVascular Clinical Trialists (CVCT) Workshop of the ESC Working Group on CardioVascular Pharmacology and Drug Therapy. Eur J Prev Cardiol (2012) 0.85
Therapeutic applications of circadian rhythms for the cardiovascular system. Front Pharmacol (2015) 0.84
What are the Evidence Based Public Health Interventions for Prevention and Control of NCDs in Relation to India? Indian J Community Med (2011) 0.84
Patients undergoing coronary revascularisation: a missed opportunity for secondary prevention? Postgrad Med J (2005) 0.84
Results of the ONTARGET and TRANSCEND studies: an update and discussion. Vasc Health Risk Manag (2009) 0.84
Effects of ACE-inhibition on IGF-1 and IGFBP-3 concentrations in older adults with high cardiovascular risk profile. J Nutr Health Aging (2010) 0.84
Nonantithrombotic medical options in acute coronary syndromes: old agents and new lines on the horizon. Circ Res (2014) 0.84
Clinical implications of the 2013 ESH/ESC hypertension guidelines: targets, choice of therapy, and blood pressure monitoring. Drugs R D (2014) 0.84
New perspectives in the renin-angiotensin-aldosterone system (RAAS) I: endogenous angiotensin converting enzyme (ACE) inhibition. PLoS One (2014) 0.84
Treating coronary disease and the impact of endothelial dysfunction. Prog Cardiovasc Dis (2014) 0.83
Augmentation of the renin-angiotensin system by hypercholesterolemia promotes vascular diseases. Future Lipidol (2008) 0.83
Efficacy and safety of fixed combinations of irbesartan/hydrochlorothiazide in hypertensive women: the inclusive trial. J Womens Health (Larchmt) (2008) 0.83
A randomized trial to assess the impact of opinion leader endorsed evidence summaries on the use of secondary prevention strategies in patients with coronary artery disease: the ESP-CAD trial protocol [NCT00175240]. Implement Sci (2006) 0.83
[Cardiovascular secondary prevention]. Clin Res Cardiol (2006) 0.82
Impact of therapy with statins, beta-blockers and angiotensin-converting enzyme inhibitors on plasma myeloperoxidase in patients with coronary artery disease. Clin Res Cardiol (2010) 0.82
Management of atherothrombotic risk factors in high-risk Canadian outpatients. Can J Cardiol (2009) 0.82
The Korean Society of Hypertension Guidelines for the Management of Hypertension in 2013: Its Essentials and Key Points. Pulse (Basel) (2015) 0.82
Angiotensin-Converting Enzyme Inhibitors (ACEIs) and Angiotensin-Receptor Blockers (ARBs) in Patients at High Risk of Cardiovascular Events: A Meta-Analysis of 10 Randomised Placebo-Controlled Trials. ISRN Cardiol (2013) 0.82
Prevention of TGFβ induction attenuates angII-stimulated vascular biglycan and atherosclerosis in Ldlr-/- mice. J Lipid Res (2013) 0.82
ACE inhibition in secondary prevention: are the results controversial? Clin Res Cardiol (2006) 0.82
ESC-CHF: guidelines for the aspirational and the practical. Heart (2006) 0.82
The level of hs-CRP in coronary artery ectasia and its response to statin and angiotensin-converting enzyme inhibitor treatment. Mediators Inflamm (2006) 0.81
Pre-hypertension: how low to go and do drugs have a role? Br J Clin Pharmacol (2012) 0.81
Arterial stiffness and pharmacological interventions--the TRanscend arterial stiffNess Substudy (TRANS study). Vasc Health Risk Manag (2007) 0.81
Renin gene polymorphisms in bangladeshi hypertensive population. J Genomics (2014) 0.81
New perspectives in the renin-angiotensin-aldosterone system (RAAS) II: albumin suppresses angiotensin converting enzyme (ACE) activity in human. PLoS One (2014) 0.81
Assessment and management of hypertension in transplant patients. J Am Soc Nephrol (2015) 0.81
Myocardial Revascularization in New York State: Variations in the PCI-to-CABG Ratio and Their Implications. J Am Heart Assoc (2012) 0.81
Reporting on sex-based analysis in clinical trials of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker efficacy. Can J Cardiol (2008) 0.81
Increased tissue angiotensin-converting enzyme activity impairs bradykinin-induced dilation of coronary arterioles in obesity. Circ J (2013) 0.80
New perspectives in the renin-angiotensin-aldosterone system (RAAS) III: endogenous inhibition of angiotensin converting enzyme (ACE) provides protection against cardiovascular diseases. PLoS One (2014) 0.80